MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome rather than nuclear DNA. It belongs to a class called mitochondrial-derived peptides (MDPs) and acts as a signaling molecule between mitochondria and the nucleus. It activates AMP-activated protein kinase (AMPK), the master metabolic switch also activated by exercise, and is often described as an "exercise mimetic" peptide. The synthetic form is administered as subcutaneous injection.

The molecule was first identified in 2015 at USC by the Cohen laboratory. Unlike the more than 20,000 peptides encoded by nuclear DNA, MOTS-c is one of a small number of biologically active peptides encoded directly by the mitochondrial genome. The 12S rRNA gene in mitochondrial DNA contains an open reading frame that encodes the MOTS-c sequence. The peptide is produced inside mitochondria, translocates to the cytoplasm and nucleus under metabolic stress, and acts as a "mitokine" or mitochondrial hormone.

CohBar Inc. licensed the technology and developed CB4211, a stabilized MOTS-c analog, through preclinical models of obesity, fibrosis, and cancer. Phase 1a/1b trials in healthy volunteers and patients with obesity and nonalcoholic steatohepatitis (NASH) (NCT03998514) completed in 2021 with reported positive results. CohBar discontinued the CB4211 program in 2022 citing formulation challenges, not efficacy or safety concerns. The company has since ceased operations.

The CohBar Phase 1 Trial

The CB4211 program was the only formal pharmaceutical development of an MOTS-c analog through human trials.

Phase 1a in healthy volunteers. Conducted in 2020 to 2021. Established safety, tolerability, and pharmacokinetic parameters in healthy adult subjects. The compound was reported to be well-tolerated with no serious adverse events.

Phase 1b in obesity and NASH. Conducted in patients with obesity and nonalcoholic steatohepatitis. Reported positive signals on metabolic biomarkers, though detailed efficacy data was not extensively published before CohBar discontinued the program.

The CohBar discontinuation in 2022 was attributed to formulation challenges rather than efficacy or safety failure. The peptide's mitochondrial-targeting mechanism appears to create delivery challenges that the company could not resolve within its development budget. No other company has picked up the program. The full Phase 1 data has not been published in a peer-reviewed journal at the time of writing.

This is the structural problem with the MOTS-c evidence base in 2026. The mechanistic and animal data is substantial. The single human pharmaceutical development program was discontinued for non-efficacy reasons. There is no active sponsor and no current registered Phase 2 program for any MOTS-c indication.

Additional Human Research

Beyond the CohBar trial, MOTS-c has been studied in observational and exercise-physiology contexts.

Exercise induction. Reynolds et al. (Nature Communications, 2021) confirmed that exercise induces endogenous MOTS-c production in human skeletal muscle. Levels increased nearly 12-fold after exercise and remained partially increased after a 4-hour rest period. Plasma MOTS-c levels increased by approximately 50 percent during and after exercise. The finding established the bidirectional relationship between MOTS-c and physical activity.

Breast cancer survivor exercise trial. A 2021 secondary analysis published in Scientific Reports examined the effects of 16-week aerobic and resistance exercise on MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Exercise increased MOTS-c, with notable ethnic-specific differences in baseline and exercise-induced levels.

Aging biomarker research. MOTS-c levels decline with age in animal models. Whether MOTS-c levels can serve as a biomarker of metabolic aging in humans is under investigation. The peptide has been proposed as both a marker and a potential intervention target for age-related metabolic decline.

MOTS-c acts on multiple cellular and systemic pathways with AMPK activation as the central mechanism.

AMPK activation. AMP-activated protein kinase is the master metabolic switch that integrates cellular energy status. When energy is low (high AMP-to-ATP ratio), AMPK activates and shifts metabolism toward energy production: glucose uptake, fatty acid oxidation, mitochondrial biogenesis. MOTS-c triggers AMPK independently of the normal AMP/ATP sensing mechanism, producing exercise-mimetic effects on metabolism.

Insulin-independent glucose uptake. MOTS-c promotes GLUT4 translocation to muscle cell membranes, allowing skeletal muscle to absorb glucose without requiring insulin signaling. This is mechanistically similar to the effect of exercise on muscle glucose uptake.

Fatty acid oxidation enhancement. Increased mitochondrial fatty acid metabolism, shifting cellular energy production toward fat as a fuel source. The metabolic effect supports body composition changes observed in animal models.

Nuclear translocation under stress. Under metabolic stress, MOTS-c translocates to the cell nucleus and directly modulates gene expression. This nucleus-targeting mechanism is distinct from typical signaling peptides and may explain the broad transcriptomic effects reported in animal models.

Folate-methionine cycle activation. MOTS-c affects one-carbon metabolism through the folate-methionine pathway, with downstream effects on methylation patterns and methyl-donor availability.

Mitochondrial biogenesis. Increased production of new mitochondria in skeletal muscle and other tissues. The effect resembles the response to endurance training.

The animal data on MOTS-c is striking. The original 2015 Cell Metabolism paper by Lee and colleagues reported that systemic MOTS-c treatment reversed diet-induced obesity and diet-and-age-dependent insulin resistance in mice. A 2021 paper in mice reported approximately doubled treadmill running capacity with MOTS-c administration in middle-aged and old animals. The exercise-mimetic claim is supported by the magnitude of these effects.

Regulatory status

MOTS-c has no FDA approval for any indication. The compound is not on the FDA Category 2 bulks list as of May 2026, which is unusual for a peptide with extensive online marketing presence. The regulatory position is informal: the compound is widely sold by online research-chemical vendors as a "research peptide" with "for laboratory use only" labeling that the resale ecosystem ignores.

The CB4211 analog from CohBar was an investigational new drug that did not proceed to FDA marketing approval before development was discontinued. No active IND for MOTS-c or its analogs is on the FDA register.

EU and UK regulators have not formally evaluated MOTS-c. There is no EMA or MHRA pathway underway. The compound has not been positioned for regulatory submission anywhere.

MOTS-c is not currently on the WADA Prohibited List as a specific named substance. As a peptide that mimics exercise effects and supports endurance capacity, it could fall under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) by analogy, particularly the "mimetics" sub-category. Athletes considering use should treat the compound as effectively prohibited pending specific WADA guidance.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The CohBar Phase 1a/1b data reportedly shown good tolerability in healthy volunteers and obese subjects, with no serious adverse events at the doses tested. Detailed safety data has not been published in peer-reviewed journals.

Expected adverse events based on mechanism include:

Injection-site reactions. Mild local effects at subcutaneous injection sites. Generally self-limited.

Hypoglycemia risk. AMPK activation and insulin-independent glucose uptake could in principle produce hypoglycemia in patients with type 1 diabetes or those on glucose-lowering medications. Not documented as a clinical signal at therapeutic doses.

Mild fatigue during dosing initiation. Some users report transient fatigue in the first weeks, possibly reflecting metabolic adaptation.

The published animal toxicology has not flagged dose-limiting toxicity. Long-term safety data in humans does not exist beyond the limited Phase 1 program. The structural lack of an active pharmaceutical sponsor means safety monitoring relies on user-reported experiences rather than systematic pharmacovigilance.

The mitochondrial peptide class includes several compounds with different mechanisms and evidence positions.

SS-31 (elamipretide, Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome. The mechanism is cardiolipin binding and inner mitochondrial membrane stabilization (structural protection). SS-31 has the largest human evidence base of any mitochondrial peptide and is the only FDA-approved option.

MOTS-c acts through AMPK activation and metabolic signaling (functional activation). The two mechanisms are complementary in principle. SS-31 protects membrane structure; MOTS-c activates metabolic pathways.

Humanin is another mitochondrial-derived peptide with primarily preclinical evidence on neuroprotection and metabolic regulation. Limited human trial data.

Other MDPs (SHLP1 through SHLP6) are additional mitochondrial-derived peptides under early investigation. None has clinical-trial-level evidence.

For mitochondrial-disease patients specifically, SS-31 is the FDA-approved option. MOTS-c remains investigational. The complementary mechanisms have led some longevity protocols to include both, though no clinical trial has tested the combination.